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Abstract
Background: Our recent cDNA microarray data showed that centromere protein F (CENP-F) is significantly
upregulated in primary cultured nasopharyngeal carcinoma (NPC) tumor cells compared with normal
nasopharyngeal epithelial cells. The goal of this study was to further investigate the levels of CENP-F expression in
NPC cell lines and tissues to clarify the clinical significance of CENP-F expression in NPC as well as the potential
therapeutic implications of CENP-F expression.
Methods: Real-time RT-PCR and western blotting were used to examine CENP-F expression levels in normal
primary nasopharyngeal epithelial cells (NPEC), immortalized nasopharyngeal epithelial cells and NPC cell lines.
Levels of CENP-F mRNA were determined by real-time RT-PCR in 23 freshly frozen nasopharyngeal biopsy tissues,
and CENP-F protein levels were detected by immunohistochemistry in paraffin sections of 202 archival NPC tissues.
Statistical analyses were applied to test for prognostic associations. The cytotoxicities of CENP-F potential target
chemicals, zoledronic acid (ZOL) and FTI-277 alone, or in combination with cisplatin, in NPC cells were determined
by the MTT assay.
Results: The levels of CENP-F mRNA and protein were higher in NPC cell lines than in normal and immortalized
NPECs. CENP-F mRNA level was upregulated in nasopharyngeal carcinoma biopsy tissues compared with
noncancerous tissues. By immunohistochemical analysis, CENP-F was highly expressed in 98 (48.5%) of 202 NPC
tissues. Statistical analysis showed that high expression of CENP-F was positively correlated with T classification (P <
0.001), clinical stage (P < 0.001), skull-base invasion (P < 0.001) and distant metastasis (P = 0.012) inversely
correlated with the overall survival time in NPC patients. Multivariate analysis showed that CENP-F expression was
an independent prognostic indicator for the survival of the patient. Moreover, we found that ZOL or FTI-277 could
significantly enhance the chemotherapeutic sensitivity of NPC cell lines (HONE1 and 6-10B) with high CENP-F
expression to cisplatin, although ZOL or FTI-277 alone only exhibited a minor inhibitory effect to NPC cells.
Conclusion: Our data suggest that CENP-F protein is a valuable marker of NPC progression, and CENP-F expression
is associated with poor overall survival of patients. In addition, our data indicate a potential benefit of combining
ZOL or FTI-277 with cisplatin in NPC suggesting that CENP-F expression may have therapeutic implications.
Background
Nasopharyngeal carcinoma (NPC) is a disease with
remarkable geographic and racial distributions world-
wide. It is one of the most common cancers in
Southeastern Asia and is highly prevalent among popu-
lations originating from Southern China where the
yearly incidence rate of NPC is 25-50 per 100,000 peo-
ple [1,2]. In North America and other western countries,
the yearly incidence is less than 1 per 100,000 [1]. NPC
is a particular type of squamous carcinoma of head and
neck associated with EBV infection, environmental fac-
tors and genetic aberrance [3]. Most NPCs are
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any medium, provided the original work is properly cited.undifferentiated or poorly differentiated with the follow-
ing characteristics: fast growth and a great tendency to
invade adjacent regions as well as metastasize to regio-
nal lymph nodes and distant organs. Although NPCs are
usually radiosensitive, local failure and metastasis still
occur [4,5]. Nasopharyngeal carcinogenesis is a multi-
step process with morphological progression involving
multiple genetic and epigenetic events [6]. Thus, identi-
fication of molecular and biological changes that occur
during carcinogenesis and progression could facilitate
investigation of the pathology of the disease and gener-
ate new prognostic markers to more accurately predict
patients’ clinical outcome, helping to individualize treat-
ments for NPC patients.
CENP-F (or mitosin) is a member of the human cen-
tromeric proteins (CENPs) family, which is involved in
centromere formation and kinetochore organization
during mitosis [7,8]. Its expression and subcellular loca-
lization patterns are regulated in a cell cycle-dependent
manner. No detectable expression of CENP-F has been
reported in G0/G1, only low levels of expression have
been detected in the nuclear matrix during S phase, and
CENP-F proteins gradually accumulate in the nucleus in
G2 then localizing to kinetochores in mitosis and reach
the maximal expression in G2 and M cells [9]. At the
end of mitosis, CENP-F is rapidly proteolyzed by the
proteasome [10]. Accumulating evidence suggests that
CENP-F is an important protein involved in chromo-
some alignment and kinetochore-microtubule interac-
tion. Depletion of CENP-F results in chromosome
misalignment and improper microtubule-kinetochore
attachment [11]. It interacts directly with many proteins
including CENP-E, NudE, ATF4, and Rb, thereby modu-
lating cell fate [12]. The kinetochore-targeting domain is
located near the C-terminus, a region that is sensitive to
farnesyltransferase inhibitors (FTIs), which can prevent
CENP-F farnesylation and cause mitotic chromosome
alignment defects [13]. A recent report showed that
zoledronic acid (ZOL) can inhibit farnesylation of
CENP-F and disrupt proper localization and functioning
of the protein [14].
Cell cycle-specific expression of CENP-F makes it a
potential marker of proliferation. Indeed, CENP-F is
correlated with tumor proliferation in a variety of
human tumors, including lung cancer [15], non-Hodg-
kin lymphoma [16], salivary gland tumors [17], and
mantle cell lymphoma [18]. CENP-F is also correlated
with early recurrence in intracranial meningiomas [19]
and poor prognosis in breast cancer [20]. The CENP-F
gene is located on 1q32-q41, which is frequently ampli-
fied in NPCs as shown by comparative genomic hybridi-
zation analysis [21]. Using a cDNA microarray, we
analyzed the global gene expression profile of primary
cultured NPC cells and found that CENP-F is
significantly upregulated in NPC cells compared with
normal nasopharyngeal epithelial cells [22].
Our previous studies raised important questions
regarding patterns of CENP-F expression in human
NPC tissues, potential correlations with clinicopatholo-
gic grade and prognosis, and its potential role in che-
motherapy. Here, we found that CENP-F was
upregulated in NPC cell lines and tissues. Immunohisto-
chemistry analysis revealed that CENP-F expression was
positively correlated with clinicopathologic features and
inversely correlated with overall survival. Cox regression
analysis identified CENP-F as an independent factor for
clinical prognosis. More importantly, we revealed that
combining cisplatin with ZOL or FTI could have syner-
gistic effects in NPC cell lines with high CENP-F
expression. Taken together, our results suggest that
CENP-F could be a potential prognostic biomarker for
clinical outcome and a promising indicator for selective
therapeutic treatment in NPC.
Results
CENP-F expression is upregulated in NPC cell lines
To investigate the expression levels of CENP-F, real-
time RT-PCR, and western blotting analysis were
conducted on the samples of normal nasopharyngeal
epithelial cells (NPEC2), the immortalized nasopharyn-
geal epithelial cells (NPEC2 Bmi-1), and various NPC
cell lines. Real-time RT-PCR revealed a higher expres-
sion of CENP-F mRNA in all the cancer cell lines than
that in NPEC2 and NPEC2 Bmi-1 cells (Fig. 1A). Con-
sistent with mRNA levels, high expression of CENP-F
protein was observed in all of the NPC cell lines,
whereas there was no detectable expression of CENP-F
in NPEC2 and NPEC2 Bmi-1 (Fig. 1B). The high expres-
sion of CENP-F was further confirmed in cancer cells
after normalized by the percentage of the cells in G2/M
(Additional file 1 Fig. S1). Thus, we concluded that all
NPC cell lines manifested higher CENP-F expression at
both the mRNA and protein levels compared with that
of normal and immortalized cells.
Overexpressions of CENP-F in NPC tissues
To determine the expression of CENP-F in NPC tissues,
real-time RT-PCR analysis was performed in 11 noncan-
cerous tissue samples and 12 NPC tissue samples.
CENP-F was found to be significantly upregulated in
NPC tissue samples compared with noncancerous sam-
ples (P = 0.0141) (Fig. 2A). To verify this observation,
we further examined the expression and localization of
CENP-F protein in 202 paraffin-embedded NPC samples
by immunohistochemical analysis. Of these archival
NPC tissues, 24 contained normal and uninvolved naso-
pharyngeal columnar epithelia and 12 contained unin-
volved nasopharyngeal squamous epithelia. CENP-F
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Strong staining of CENP-F protein was detected in 98
(48.5%) tumors. As shown in Fig. 2, CENP-F specific
expression was observed in tumor cells but not in the
uninvolved nasopharyngeal epithelia (Fig. 2B). Specific
CENP-F was predominantly found to be expressed in
carcinoma cells (Fig. 2D-F). However, there was no cor-
relation between the number of CENP-F expressing
cells and the number of mitotic cells (Additional file 2
Fig. S2). In contrast, no positive staining or only mar-
ginal staining was detected in adjacent noncancerous
epithelial cells (Fig. 2C). CENP-F was mainly expressed
in the nuclei of tumor cells and preferentially located at
the tumor invasive front (Fig. 2E and 2F). These data
suggest that CENP-F is overexpressed in NPC samples,
especially in the invasive front, which indicates a poten-
tial role in promoting tumor invasion.
Positive correlation of CENP-F expression with
clinicopathologic features
Immunohistochemical determination of CENP-F levels
was statistically analyzed to identify an association with
the clinicopathologic features of NPC. As shown in Table
1, CENP-F expression was significantly correlated with T
classification (P < 0.001), clinical stage (92 stage) (P <
0.001), skull-base invasion (P < 0.001), and distant metas-
tasis (P = 0.012). However, there was no significant corre-
lation between CENP-F expression and age, gender,
histological classification, or N classification. Spearman
correlation analysis showed CENP-F expression levels
Figure 1 Expression analysis of CENP-F mRNA and protein in nasopharyngeal epithelial cells. A. Real-time RT-PCR analysis of CENP-F
mRNA in normal nasopharyngeal epithelial cells (NPEC2), immortalized nasopharyngeal epithelial cell line (NPEC2 Bmi-1) and NPC cell lines
(CNE1, CNE2, SUNE1, 6-10B, HNE1, HONE1 and C666). B. Western blot analysis of CENP-F protein in the same cell lines as described in A.
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Page 3 of 13were positively correlated with clinical stage (r = 0.395; P <
0.001), T classification (r = 0.359; P < 0.001), skull-base
invasion (r = 0.245; P < 0.001), and distant metastasis (r =
0.177; P = 0.012) (Table 2). Our data indicates that high
CENP-F expression significantly correlated with advanced
tumor stage, local invasion, and clinical progress.
Inverse correlation of CENP-F expression with patients’
survival
We next evaluated whether the level of CENP-F
expression was associated with patient prognosis. The
median follow-up time for the 202 cases was 85
months with a range from 3 to 148 months. As shown
in Fig. 3, the survival time was significantly different
between the groups (P < 0.001); the low CENP-F
expression group had a longer overall survival time,
whereas the high CENP-F expression group had a
shorter overall survival time. The cumulative 5-year
survival rate was 78.6% (95% confidence interval,
0.708-0.864) in the low CENP-F group, but it was only
53.6% (95% confidence interval, 0.436-0.636) in the
high CENP-F group.
Figure 2 Expression analysis of CENP-F mRNA and protein in NPC samples. A. Real-time RT-PCR analysis of CENP-F mRNA in normal
nasopharyngeal biopsies (Normal) and nasopharyngeal carcinoma biopsies (NPC). B-F. Immunohistochemistry analysis of CENP-F expression in
archived NPC tissue. CENP-F specific expression is observed in tumor cells and not in the uninvolved nasopharyngeal epithelia (B). CENP-F is not
expressed in normal epithelial cells (C). CENP-F expression was mainly localized within nuclei of cancer cells (D, E and F), and its expression was
observed mainly in the invasive front areas (E and F). B (×100), E (×200) and C, D, F (×400).
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tion, N classification, distant metastasis, clinical stage (92
stage), and skull-base invasion were also significantly cor-
related with survival in Kaplan-Meier analysis and Log-
rank test (for gender, P = 0.036; for T classification, N
classification, distance metastasis, clinical stage, and skull-
base invasion, P < 0.001). Univariate analysis showed that
gender, clinical stage, skull-base invasion and CENP-F
expression were statistically significant prognostic factors.
However, clinical prognosis was not associated with age or
histological classification. Multivariate analysis including
CENP-F expression level, gender, clinical stage, and skull-
base invasion demonstrated that CENP-F expression level
(P = 0.045) and clinical stage (P <0 . 0 0 1 )w e r ei n d e p e n d e n t
prognostic factors for NPC, whereas gender and skull-base
invasion were not independent predictors (Table 3). Thus,
our findings indicate that CENP-F expression level, as an
independent prognostic factor, is inversely associated with
clinical prognosis of NPC.
ZOL Synergizes with cisplatin to enhance the cytotoxicity
on CENP-F high expressing cells
Recently, CENP-F was suggested to be a potential new
molecular target contributing to the anti-tumor effects
o fZ O Li nb r e a s tc a n c e rc e l l s[ 1 4 ] .A so v e r e x p r e s s i o no f
CENP-F was commonly observed in NPC cell lines and
tissues, we then analyzed whether NPC cell lines were
sensitive to ZOL treatment. As shown by the dose-
response curves in Fig. 4, treatment with ZOL alone
only exhibited a minor inhibitory effect, and the survival
rate of all five cell lines was still more than 60% even at
high doses (50 μM). The results indicate that ZOL alone
has little cytotoxicity and cannot inhibit proliferation in
either immortalized nasopharyngeal epithelial cells with
low expression of CENP-F (NPEC2 Bmi-1) or NPC cell
lines with elevated expression of CENP-F.
Most chemotherapies for NPC are cisplatin-based
combinations [23]; therefore, we explored whether ZOL
could enhance the cytotoxic activity of cisplatin. Consid-
e r i n gt h a tt h ep e a ks e r u mc o n c e n t r a t i o n so fZ O Lf o l -
lowing 4 mg standard dose is approximately 1-2 μM
before localization to the bone [24], 2 μMZ O Lw a s
used in combination with cisplatin at various
Table 1 Correlation between the clinicopathologic
features and expression of CENP-F protein
Characteristics CENP-F (%) P
Low
expression
High
expression
Gender
Male 73 (48.3) 78 (51.7)
Female 31 (60.7) 20 (39.3) 0.124
Age (y)
≤ 45 49 (54.4) 41(45.6)
> 45 55 (49.1) 57 (50.9) 0.451
Histologic
classification
Type II 4 (40.0) 6 (60.0)
Type III 100 (52.1) 92 (47.9) 0.528*
Clinical stage (92
stage)
I-II 65 (75.6) 21 (24.4)
III-IV 39(33.6) 77 (66.4) < 0.001
T classification
T1-T2 82 (66.1) 42 (33.9)
T3-T4 22 (28.2) 56 (71.8) < 0.001
N classification
N0 65 (55.1) 53 (44.9)
N1-3 39 (46.4) 45 (53.6) 0.225
Distant metastases
No 97 (54.8) 80(45.2)
Yes 7 (28.0) 18 (72.0) 0.012
Skull-base invasion
No 92 (57.9) 67 (42.1)
Yes 12(27.9) 31 (72.1) < 0.001
*. Fisher’s exact test.
Table 2 Spearman correlation analysis between CENP-F
and clinicopathologic factors
Variables CENP-F expression level
Spearman correlation P-value
Clinical stage 0.395 < 0.001
T classification 0.359 < 0.001
Skull-base invasion 0.245 < 0.001
Distant metastases 0.177 0.012
Figure 3 Kaplan-Meier curves with univariate analyses (log-
rank) for patients with low CENP-F expression (dotted line)
versus high CENP-F expressing (bold line) groups. The 5-year
overall survival rates were 78.6% in the low CENP-F expression
group (n = 104), whereas the 5-year overall survival rates were
53.6% in the high expression group (n = 98).
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interactions between two drugs in five cell lines by the
MTT assay. The dose-response curves and the mean
IC50 values are shown in Fig. 5A-E. In HONE1 and 6-
10B cell lines, which showed high expression of CENP-
F, the dose-response curves of cisplatin were clearly
shifted to left by ZOL, and the IC50 changed over 2-
fold in combination with ZOL (from 8.10 ± 1.61 μM,
4.03 ± 0.74 μM to 3.93 ± 0.76 μM, 1.88 ± 0.39 μM,
respectively) (Fig. 5A and 5B). In CNE1 and SUNE1 cell
lines, which showed medium expression of CENP-F, the
dose-response curves of cisplatin were slightly shifted to
left by ZOL, and the IC50 changed less than 2-fold in
combination with ZOL (from 4.31 ± 1.01 μM, 3.27 ±
0.60 μMt o3 . 4 4±0 . 8 7μM, 2.47 ± 0.43 μM, respec-
t i v e l y )( F i g .5 Ca n d5 D ) .H o w e v e r ,i nN P E C 2B m i - 1
cells, which showed low expression of CENP-F, the
dose-response curve of cisplatin was not shifted by
ZOL, and the IC50 was not changed obviously by com-
bination with ZOL (from 7.37 ± 1.25 μM to 6.82 ± 1.49
μM) (Fig. 5E). To avoid masking the enhanced cytotoxic
effect, we then selected the concentration of cisplatin to
obtain an approximately 30% inhibition of proliferation
in vitro. Analysis demonstrated that the cytotoxic effect
with addition of ZOL was different from cisplatin alone
in four NPC cell lines (for HONE1 and 6-10B, P <0 . 0 1 ;
for CNE1 and SUNE1, P < 0.05), but not in immorta-
lized cell lines (P > 0.05) (Fig. 5F).
We then evaluated the potential synergistic effects of
the combination of ZOL and cisplatin by the Zheng-Jun
Jin method. In HONE1 and 6-10B cells, synergy was
seen after treatment with 2 μM ZOL (Q = 1.54 and Q =
1.30, respectively). In CNE1 and SUNE1 cells, additivity
was seen after treatment with 2 μM ZOL (Q = 0.98, Q
= 0.88, respectively), whereas in NPEC2 Bmi-1, only a
marginal effect was observed (Q = 0.85). These results
indicates that the growth inhibition activity of ZOL in
combination with cisplatin in NPC cells was correlated
with the expression level of CENP-F in the cells, and a
synergistic interaction from combining ZOL and cispla-
tin was only observed in CENP-F high expression NPC
cells (HONE1 and 6-10B).
FTI-277 Synergizes with cisplatin to enhance the
cytotoxicity on high CENP-F expression cells
To determine whether these observations could be
extended to other agents affecting CENP-F functionality,
we did similar experiments in CNE1 and HONE1 with
the commercially-available chemical FTI-277, which tar-
gets farnesyl transferase. The dose-response curves of
FTI-277 are shown in Fig. 6A. We found that the dose-
response curves of cisplatin in combination with 1 μM
FTI-277 were clearly shifted to left (Fig. 6B), and the Q
value was 1.343 in HONE1 cells, whereas, the dose-
response curves of cisplatin were slightly shifted to left
by FTI-277 (Fig. 6C) and the Q value was 1.075 in
CNE1 cells. We also used the immunofluorescence
Figure 4 Dose-response curves for ZOL. The viability of each cell
line (NPEC2 Bmi-1 cell line (black triangle), CNE1 cell line (gray
circle), SUNE1 cell line (gray triangle), HONE1 cell line (black circle),
6-10B cell line (black square)) was plotted against the concentration
of drug used in a 72 h treatment. Each data point represents the
geometric mean of at least three independent experiments.
Table 3 Univariate and multivariate analysis of different prognostic variables in patients with NPC by Cox regression
analysis
Univariate analysis Multivariate analysis
P HR (95% CI) P HR (95% CI)
Gender
Female vs. Male 0.039 0.557 (0.319-0.971) 0.190 0.686 (0.390-1.205)
Clinical Stage
III-IV vs. I-II < 0.001 3.188 (1.964-5.175) < 0.001 2.660 (1.588-4.457)
Skull-base invasion
Yes vs. No < 0.001 2.344 (1.482-3.706) 0.229 1.355 (0.825-2.225)
Expression of CENP-F
High vs. Low 0.001 2.269 (1.472-3.498) 0.045 1.604 (1.011-2.543)
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Page 6 of 13Figure 5 The cytotoxic effect of cisplatin alone or in combination with ZOL. A-E. Shifting of dose-response curves of cisplatin by ZOL. Five
nasopharyngeal epithelial cells (HONE1(A), 6-10B (B), CNE1 (C), SUNE1 (D) and NPEC2 Bmi-1 (E)) were assayed using MTT assay. The dose-
response curves of cisplatin in the presence of ZOL (black square) or the absence of ZOL (triangle). The IC50 values are shown. F. ZOL
potentiated effect of cisplatin in all five nasopharyngeal epithelial cells. The concentrations of the drugs used are shown below the names of the
cell lines, NPEBmi-1 represents NPEC2 Bmi-1. Columns, mean of triplicate determinations; bars, SD. * represents P < 0.05, ** represents P < 0.01
cisplatin plus ZOL versus cisplatin alone, Student’s t test. Experiments were repeated at least three times and a representative experiment is
shown.
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CENP-F expression and chromosome localization in
HONE1 cells. As shown in Fig. 6D, CENP-F was appar-
ently reduced in metaphase, and the misaligned chro-
mosome was observed, which might correlate with the
reduced CENP-F. Therefore, we concluded that FTI-277
enhanced the cytotoxic effect of cisplatin in high CENP-
F expression NPC cells, which correlated with inhibition
of CENP-F in the cells.
Discussion
In this study, we revealed that CENP-F is upregulated in
NPC cell lines and NPC specimens at both the mRNA
and protein levels in comparison with noncancerous
Figure 6 FTI-277 Synergizes with cisplatin to enhance the cytotoxicity on high CENP-F expression cells. A. Dose-response curves for FTI-
277. The viability of each cell line (CNE1 cell line (triangle), HONE1 cell line (black square)) was plotted against the concentration of drug used in
a 72 h treatment. B-C. Shifting of dose-response curves of cisplatin by ZOL. HONE1 (B) and CNE1 (C) were assayed using MTT assay. The dose-
response curves of cisplatin in the presence of ZOL (black square) or the absence of ZOL (triangle). The IC50 values are shown. D. ZOL or FTI-277
reduces CENP-F from the kinetochore during metaphase and presents misaligned chromosomes. Immunofluorescence staining of Tubulin, DNA
and CENP-F in untreated and drug treated HONE1 cells. Representative mitotic cells in metaphase are shown for control and drug treated cells.
Bar,5μm. Experiments were repeated at least three times and a representative experiment is shown.
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sion of CENP-F was significantly associated with
advanced clinical stage, higher T classification, skull-
base invasion, and distant metastasis. Moreover, as an
independent prognostic factor, overexpression of CENP-
F was inversely correlated with the prognosis of NPC
patients. Additionally, we found that ZOL or FTI-277
could significantly enhance the chemosensitivity to cis-
platin of NPC cell lines with high expression of CENP-
F, but not in cell lines with low expression of CENP-F,
suggesting that CENP-F is a potential target of ZOL or
FTI-277 and expression of CENP-F has potential thera-
peutic implications in NPC chemotherapy.
Our study suggests that CENP-F plays an important
role in the progression of NPC. Upregulation of CENP-
F was identified at both the transcriptional and transla-
tional levels in NPC cell lines in comparison with a pri-
mary NPEC2 and an immortalized NPEC2 Bmi-1 cells.
In addition, high levels of CENP-F were detected in
approximately half (48.5%) of NPC lesions. The impor-
tance of CENP-F in the progression of NPC was further
highlighted by our finding that it is correlated with
advanced stages and T classification, which was in gen-
eral agreement with other tumor types [17,20,25,26].
Importantly, the current study was the first to identify
an inverse correlation of CENP-F with skull-base inva-
sion and distant metastasis, strongly suggesting that
CENP-F could be used as a valuable factor to identify
subsets of NPC patients with more aggressive tumors.
Finally, our data show that the high expression of
CENP-F correlates with poor prognosis and that the
level of CENP-F is a potential independent prognostic
factor for NPC, suggesting a function of CENP-F upre-
gulation in the multistage pathogenesis of this disease.
These findings are consistent with a previous study on
breast cancer [20].
A large amount of data collected from human tumors
suggests that chromosome instability (CIN) plays a cau-
sative role in a substantial proportion of malignancies
and correlates with tumor grade and prognosis [27,28].
CIN, which arises as a result of an abnormal mitosis,
can occur because of alterations in mitotic timing, mito-
tic checkpoint control, or of microtubule or centrosome
dynamics [29]. CIN is commonly found in NPC and is
thought to play a contributory role in tumor initiation
and progression [30]. Many kinetochore proteins are
proved to be associated with CIN. CENP-E is required
for efficient capture and attachment of spindle microtu-
bules and responsible for mitotic checkpoint signal
transduction [31,32]. Evidence has shown CENP-E silen-
cing leads CIN [33]. Recent research has revealed that
CENP-H was upregulated in primary human colorectal
cancers, and ectopic overexpression of CENP-H corre-
lated with chromosome missegregation and aneuploidy
[ 3 4 ] .W eh a v ep r e v i o u s l ys h o w nt h a tC E N P - Hw a sa l s o
u p r e g u l a t e di nm o s tN P Ct i s s ues [35]. The overexpres-
sion of CENP-F could affect other centromere-kineto-
chore components and disrupt normal kinetochore
function, consequently causing mitotic delay and lagging
chromosomes. Those might contribute to chromosome
instability and induce the progression of NPC. A study
on primary breast cancer showed that CENP-F expres-
sion was associated with CIN, including cyclin E overex-
pression, nuclear expression of survivin, c-Myc
amplification, aneuploid, and high telomerase activity
and poor prognosis [20]. Other studies in CENP-F
depleted U2OS cells showed chromosome alignment
defects, but the cells still proceeded through mitosis and
became aneuploid [7]. These results suggested that the
relationship between kinetochore proteins may be cru-
cial for appropriate localization and proper functioning
of the kinetochore. Our study has also provided new
insight into CIN in NPC. However, further studies are
needed to clarify the possible link between the biological
function of CENP-F and chromosome instability in
NPC, which will provide important mechanistic under-
standing of the role of CENP-F in the development and
progression of NPC.
In addition to serving as a potential prognostic bio-
marker, our in vitro findings suggest that CENP-F may
have a therapeutic implication. Numerous studies in
vitro have shown that ZOL exerts a direct cytotoxic
effect on tumor cells via inhibition of cell growth and
induction of cell apoptosis, in addition to its effect on
osteoclasts [36,37]. A recent study on breast cancer
identified CENP-F as a potential new molecular target
for ZOL, which can cause the loss of CENP-F from the
kinetochore by inhibiting farnesylation and be involved
in the antitumor effect by impairing correct chromo-
some separation [14]. Interestingly, our results did not
show a direct antitumor effect of ZOL alone even at
concentrations of 50 μM, which were not achievable in
vivo, either in immortalized NPEC2 Bmi-1 or in NPC
cell lines. Those data indicate that ZOL alone cannot
suppress the proliferation of NPC cells at clinically rele-
vant concentrations. However, a synergistic effect was
observed when cells were treated with cisplatin in com-
bination with a clinically relevant concentration of ZOL
in high CENP-F expression NPC cells. An additive effect
was observed in medium CENP-F expression cells and
only a marginal effect was observed in low CENP-F
expressing immortalized cells. Likewise, the combination
of FTI-277 with cisplatin has been shown to have simi-
lar synergistic effects against high CENP-F expression
cells. These results suggest that the effects of combined
treatments are correlated with high CENP-F expression.
Moreover, we found ZOL or FTI-277 causes the reduc-
tion of CENP-F from the kinetochore, which is
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cells [14] and head and neck tumor samples [13]. In
addition, these results indicate that the inhibition of
CENP-F might be involved in the synergistic interaction.
However, the molecular mechanism underlying the
synergistic effects in high CENP-F expression cells is
not known, and further work is required in order to
confirm this effect. Both CENP-E and CENP-F are
found on the kinetochores alongside microtubules and
specifically localize to the outer kinetochore plate during
M-phase. A recent report has identified that an allos-
teric inhibitor of CENP-E motor activity can decrease
CENP-E function and induce tumor cell apoptosis and
tumor regression [38]. Thus, it will be important to
identify novel chemicals, which target CENP-F more
specifically, in order to understanding of the role of
CENP-F in the development and progression of NPC as
well as for the development of a novel targeted therapy.
Conclusion
We found that CENP-F is overexpressed in NPC tissues
and is positively correlated with the malignant status of
NPC. High CENP-F expression is a significant prognos-
tic factor indicating poor survival in NPC patients. Our
in vitro findings suggest that combining cisplatin and
ZOL has a synergistic effect only in high CENP-F
expression NPC cells. CENP-F expression status may
have important therapeutic implications for combination
treatment and may be useful to stratify patients to
decide on an effective strategy for anticancer therapy.
Methods
Patients
Freshly frozen tissue samples of twelve nasopharyngeal
carcinoma biopsies and eleven noncancerous nasophar-
yngeal biopsies were obtained under fiberoptic naso-
pharyngoscopy from the Department of Nasopharyngeal
Carcinoma, Sun Yat-sen University Cancer Center. A
total of 202 paraffin-embedded NPC samples, which
were histologically and clinically diagnosed between
1996 and 1999 at the Cancer Center, Sun Yat-sen Uni-
versity, were also included in this study. Patients’ con-
sent and approval from the Institute Research Ethics
Committee was obtained prior to the use of these clini-
cal materials for research purposes. The clinical charac-
teristics of the NPC patients are described in detail in
Table 4. There were 151 men and 51 women, with a
median age of 48 years (ranging from 13 to 74 years).
The routine staging workup included a detailed clinical
examination of the head and neck, fiberoptic nasophar-
yngoscopy, computed tomography (CT) imaging of the
entire neck from the base of the skull, chest radiogra-
phy, abdominal sonography, a complete blood count,
and a biochemical profile. All patients’ disease stages
were classified, or reclassified, according to the 1992
NPC staging system of China as described previously
[2]. Clinical follow-up information was obtained from
the patients’ records.
Chemicals
Zoledronic acid (ZOL) was supplied by Novartis Pharma
AG (Stein, Switzerland). ZOL was dissolved in 0.9%
NaCl solution as a 5 mM stock solution and stored at
-20°C. FTI-277 was purchased from Sigma Chemical Co
(St. Louis, MO, USA). The chemical was dissolved in
Table 4 Clinicopathologic characteristics of 202 patients
and expression of CENP-F
Factors N (%)
Gender
Male 151 (74.8)
Female 51 (25.2)
Age (y)
≤ 45 90 (44.6)
> 45 112 (55.4)
Histologic classification (WHO)
Type II 10 (5.0)
Type III 192 (95.0)
Clinical stage (92 stage)
I 27 (13.4)
II 59 (29.2)
III 49(24.2)
IV 67 (33.2)
T classification
T1 83 (41.1)
T2 41 (20.3)
T3 40 (19.8)
T4 38(18.8)
N classification
N0 118 (58.4)
N1 33 (16.3)
N2 29 (14.4)
N3 22 (10.9)
Distant metastases
No 177 (87.6)
Yes 25 (12.4)
Living status (at last follow-up)
Alive 114 (56.4)
Death from NPC 88(43.6)
Skull-base invasion
No 159(78.7)
Yes 43 (21.3)
Expression of CENP-F
Low 104 (51.5)
High 98 (48.5)
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stored at -20°C. The chemicals were diluted in fresh
media before each experiment.
Cell culture
Primary NPEC2 cultures and immortalized NPEC2
induced with Bmi-1 were established as described pre-
viously [39], and grown in keratinocyte/serum-free med-
ium (Invitrogen, Carlsbad, CA). The NPC cell lines
CNE1, CNE2, HNE1, HONE1, SUNE-1, 6-10B and
C666 were maintained in RPMI 1640 (Invitrogen, Carls-
bad, CA) supplemented with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT), penicillin (100 units/ml),
and streptomycin (100 units/ml) at 37°C in a humidified
5% CO2 incubator.
Real-time RT-PCR
Total RNA from different cell lines and human tissues
were extracted using Trizol reagent (Invitrogen, Carlsbad,
CA). After reverse transcription of the total RNA, the
first-strand cDNA was then used as a template for detect-
ing of CENP-F expression. Real-time PCR and data collec-
tion were performed with an ABI PRISM 7900HT
sequence detection system. The housekeeping gene
GAPDH was used as an internal control to normalize the
expression levels of CENP-F. The primer sequences are
sense 5’- GTAGAGGACCAACACCTGCTACC-3’,a n t i -
sense 5’-GTCAGCAAACCCTTTCTTTACAACT-3’ for
CENP-F, and sense 5’-CTCCTCCTGTTCGACAGT-
CAGC-3’,a n t i s e n s e5 ’- CCCAATACGACCAAATC
CGTT-3’ for GAPDH. To ensure reproducibility of results,
all genes were tested in triplicate.
Western blot analysis
Western blot analysis was performed as described pre-
viously [39]. Briefly, cells were harvested and lysed in
lysis buffer. The protein concentration was determined
by the Bradford dye method (Bio-Rad Laboratories,
Hercules, CA). Equal amounts of cell extract were sub-
jected to electrophoresis in 4% SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes
(Amersham Pharmacia Biotech, Piscataway, NJ). The
membrane was probed with an anti-CENP-F rabbit
polyclonal antibody (1:1000; Bethyl Laboratories, Mon-
tgomery, TX). Expression of CENP-F was determined
with horseradish peroxidase-conjugated anti-rabbit
immunoglobulin G (1:2000; Santa Cruz Biotechnology,
Santa Cruz, CA) and enhanced chemiluminescence
(Amersham Pharmacia Biotech, Piscataway, NJ)
according to the manufacturer’s suggested protocols.
An anti-a-tubulin mouse monoclonal antibody (1:1000;
Santa Cruz Biotechnology) was used to confirm equal
loading.
Immunohistochemical staining (IHC)
IHC staining was performed using the Dako Envision sys-
tem (Dako, Carpinteria, CA) following the manufacturer’s
recommended protocols. All paraffin-embedded speci-
mens were cut into 4 μm sections and baked for 1 h at 65°
C. All sections were deparaffinized with xylenes and rehy-
drated with graded ethanol to distilled water. Sections
were submerged in EDTA antigen retrieval buffer (pH 8.0)
and microwaved for antigen retrieval. After being treated
with 0.3% H2O2 for 15 min to block the endogenous per-
oxidase, the section were treated with normal goat serum
for 30 min to reduce the nonspecific binding and then
rabbit polyclonal anti-CENP-F antibody (1:200; Bethyl
Laboratories) overnight at 4°C. After washing, the sections
were incubated with biotinylated anti-rabbit secondary
antibody (Zymed) followed by further incubation with
streptavidin-horseradish peroxidase (Zymed) at 37°C for
30 min. For color reaction, diaminobenzidine (DAB) was
used. For negative controls, the antibody was replaced by
normal goat serum.
The immunohistochemically stained tissue sections
were scored independently by two pathologists blinded
to the clinical parameters. The final score for CENP-F
was the average of the scores obtained by the two obser-
vers. Cases with major discrepancies in scoring (i.e., > 1)
were reviewed by both observers on a multiheaded
microscope. Based on previous studies [40,41], we used
the intensity and extent of the staining to assess CENP-
F. The entire tissue section was observed to assign
scores. The staining intensity was scored as 0 (no stain-
ing), 1 (weak staining exhibited as light yellow), 2 (mod-
erate staining exhibited as yellow brown), or 3 (strong
staining exhibited as brown). Extent of staining was
scored as 0 (0%), 1 (1 to 25%), 2 (26 to 50%), 3 (51 to
75%), or 4 (76 to 100%), according to the percentages of
the positive staining areas in relation to the whole carci-
noma area or entire section for the normal samples.
The sum of the intensity and extent scores was used as
the final staining score (0 to 7) for CENP-F. For the
purpose of statistical evaluation, tumors having a final
staining score of < 3 were grouped into low CENP-F
expression and those with scores ≥3 were grouped into
high CENP-F expression.
In Vitro Cytotoxicity Assays
Cytotoxicity tests were evaluated by 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma, St. Louis, MO, USA) assay. Cells were grown in
96-well microtiter plates at appropriate densities and
allowed to adhere for 24 h before addition of ZOL or
FTI-277 alone or cisplatin and ZOL or FTI-277 together.
To determine the cytotoxicity of ZOL and FTI-277, cells
were exposed to increasing concentrations ranging from
Cao et al. Molecular Cancer 2010, 9:237
http://www.molecular-cancer.com/content/9/1/237
Page 11 of 130.1 μMt o5 0μM for 72 h. The absorbance was deter-
mined at 570 nm in a multi-detection microplate reader
(SpectraMax M5). To test the effect of ZOL or FTI-277
on the chemosensitivity of immortalized NPEC and NPC
cells, ZOL (2 μM) was added to the medium with various
concentrations of cisplatin in NPEC2-Bmi-1, SUNE1,
CNE1, HONE-1 and 6-10B, and FTI-277 (1 μM) was
added in CNE1 and HONE1. The concentrations
required to inhibit growth by 50% (IC50) were calculated
from survival curves using the Bliss method [42]. The
results from the assays were analyzed for the combina-
tion effect between ZOL and cisplatin according to the
Zheng-Jun Jin method [43]. This method provides a Q
value, where Q < 0.85 indicates antagonism, 0.85 ≤ Q<
1.15 indicates additivity and Q≥ 1.15 indicates synergism.
The formula is Q = Ea+b/(Ea+Eb-Ea×Eb), where Ea+b,E a
and Eb are the average effects of the combination treat-
ment, ZOL only and cisplatin only, respectively. All treat-
ments were performed in quadruplicate and experiments
were repeated three times.
Immunofluorescence analysis
Immunofluorescence analysis was performed as
described previously [39]. Cell lines were plated on cul-
ture slides (Costar, Cambridge, MA), treated with ZOL
or FTI-277 for 24 h, then fixed in ice-cold acetone for 5
min at -20°C. The cells were blocked for 30 min in 10%
B S A( S i g m a - A l d r i c hS t .L o u i s ,M O )i nP B Sa n dt h e n
incubated with rabbit polyclonal anti-CENP-F antibody
(1:200; Bethyl Laboratories) for 2 hours at room tempera-
ture. After three washes in PBS, the slides were incubated
for 1 h in the dark with secondary goat anti-rabbit anti-
bodies (Invitrogen, Carlsbad, CA). After three further
washes, the slides were stained with 4-,6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich St. Louis, MO) for 5
min to visualize the nuclei, and examined using an Olym-
pus confocal imaging system (Olympus FV100).
Statistical analysis
All statistical analyses were carried out using the SPSS
13.0 statistical software package. The significance of
CENP-F mRNA levels and the MTT assays were deter-
mined by t-tests. Chi-square and Fisher’s exact tests
were used to analyze the relationship between CENP-F
expression and clinicopathologic characteristics. Bivari-
ate correlations between variables were calculated by
Spearman’s rank correlation coefficients. Survival curves
were plotted by the Kaplan-Meier method and com-
pared by log-rank test. Univariate and multivariate
regression analyses were performed with the Cox pro-
portional hazards regression model to analyze indepen-
dent factors affecting prognosis. P < 0.05 was considered
statistically significant.
Additional material
Additional file 1: Fig.S1 Expression of CENP-F is elevated in NPC cell
lines by normalizing to the percentage of cells in G2/M.A .
Immortalized nasopharyngeal epithelial cells (NPEC2 Bmi-1) and NPC cells
(CNE1, SUNE1, CNE2, 6-10B, HONE1 and C666) were stained for DNA
content and analyzed by flow cytometry, n = 3. B. Western blot analysis of
CENP-F protein in the same cell lines as described in A. Relative expression
levels of CENP-F were determined from the Western blot using Image J
program. C. Quantitative analysis of the relative levels of CENP-F by
normalizing to the percentage of cells in G2/M. Bars, SD, n =3 .
Additional file 2: Fig.S2 CENP-F protein is overexpressed in NPC
tissue samples by normalizing to the percentage of cells in mitosis.
H&E and immunohistochemical stained-slides were used for calculating
the percentage of mitotic cells and CENP-F positive cells in high CENP-F
expression group and low CENP-F expression group. A. Representative
fields are shown by H&E staining of the NPC tissue samples. B-C.
Representative fields are shown by immunohistochemical staining in low
CENP-F expression group (B) and high CENP-F expression group (C).
Insets, a magnified image of the cell indicated with the arrow. Bar, 10
μm. D. Quantitative analysis of the mitotic cells in high CENP-F
expression group and low CENP-F expression group. 50 cases from
CENP-F high expression group (n = 25) and low expression group (n =
25) were picked, and ten independent and intact microscopic fields
(×400), representing the NPC cancer nest, were analyzed for each case.
The results were expressed as the mean (+SD) percentage of number
cells, * represents P < 0.001, CENP-F high expression group versus low
expression group, Student’s t test. A-C (×400).
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